B-cell Lymphoma
Conditions
Keywords
Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor
Brief summary
The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.
Interventions
DRUGParsaclisib
Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
DRUGRituximab
Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
DRUGBendamustine
Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
DRUGIbrutinib
Ibrutinib administered orally once daily.
Sponsors
Incyte Corporation
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women, aged 18 years or older on the day of signing the Informed Consent Form (ICF). * Histologically confirmed indolent/aggressive DLBCL, FL, MZL, or MCL. * Participants with DLBCL, MZL or MCL must have received at least 1 prior line of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen. * Participants with FL must have received at least 2 prior lines of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen. * Ineligible for stem cell transplant. * Participants with DLBCL must have failed or refused stem cell transplantation or failed first-line salvage therapy if ineligible for transplantation. * Must be willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue. * Life expectancy of \> 3 months. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 (see Appendix D). * Willingness to avoid pregnancy or fathering a child. * Ability to comprehend and willingness to sign an ICF
Exclusion criteria
* Evidence of transformed non-Hodgkin lymphoma histologies (with the exception of FL). * Histologically confirmed rare non-Hodgkin B-cell subtypes. * History of or central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease. * Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K inhibitor. * For participants to be treated with bendamustine (Treatment B), prior treatment with bendamustine (within 12 months of the start of study treatment). Participants with prior bendamustine treatment (\> 12 months before the start of study treatment) are eligible if they meet the following criteria: * Did not discontinue because of tolerability concerns. * Achieved either partial response (PR) or complete response (CR) to the bendamustine regimen of at least 12 months in duration before relapse/progression. * Experienced progression following a regimen containing an alkylating agent. * For participants to be treated with ibrutinib (Treatment C), prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor. * Allogeneic stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment. * Active graft-versus-host disease following allogeneic transplant. * Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of treatment-emergent adverse events (TEAEs) | Up to approximately 12 months. | A TEAE is any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Apparent clearance of parsaclisibin combination with rituximab, bendamustine and rituximab, or ibrutinib | Up to approximately 1 month. | Measured to assess the plasma pharmacokinetic profile of parsaclisib in combination with rituximab, bendamustine and rituximab, and ibrutinib. |
| Apparent volume of distribution of parsaclisib in combination with rituximab, bendamustine and rituximab, or ibrutinib | Up to approximately 1 month. | Measured to assess the plasma pharmacokinetic profile of parsaclisib in combination with rituximab, bendamustine and rituximab, and ibrutinib. |
Countries
Italy, Spain, United States
Outcome results
None listed